Celcuity Announces Key Presentations at Investor Conferences
Upcoming Investor Conferences for Celcuity Inc.
Celcuity Inc. (Nasdaq: CELC), a pioneering biotechnology firm focused on targeted therapies in oncology, has exciting news to share. The company's CEO and co-founder, Brian Sullivan, is set to engage with investors during two significant upcoming conferences. These conferences provide a platform for Celcuity to showcase their advancements in cancer treatment and discuss the future of oncology therapies.
Details of the Presentations
TD Cowen Oncology Innovation Summit
Brian Sullivan will participate in a fireside chat during the TD Cowen's 6th Annual Oncology Innovation Summit. This event is scheduled for 9:30 a.m. ET, where he will provide insights into Celcuity's strategic vision and innovative approaches to oncology therapy development. Investors can look forward to gaining valuable perspectives during this session.
Jefferies Global Healthcare Conference
Following the TD Cowen event, Sullivan will also be present at the Jefferies Global Healthcare Conference. This engagement is set for 7:35 a.m. ET. Similar to the previous conference, attendees will have the opportunity to see how Celcuity plans to reshape the oncology landscape with their targeted therapies.
Accessing the Webcasts
For those wishing to tune in to these events remotely, both presentations will be streamed live. Interested investors can find the webcasts in the Investors section of Celcuity's official website. Notably, a replay of each session will be made available shortly after they conclude, allowing for further analysis and review.
Celcuity's Commitment to Oncology
Celcuity is at the forefront of developing targeted therapies aimed at treating various solid tumors. The lead candidate, gedatolisib, represents a significant advancement in the field. This potent inhibitor targets the PI3K/AKT/mTOR pathway, a crucial mechanism implicated in multiple cancers. Unlike many conventionally approved therapies that target a single pathway, gedatolisib offers a comprehensive approach by blocking multiple components.
Current Clinical Trials
Currently, Celcuity is evaluating gedatolisib through rigorous clinical trials. A pivotal Phase 3 trial named VIKTORIA-1 is assessing its efficacy in combination with fulvestrant, with or without the addition of palbociclib for patients diagnosed with HR+/HER2- advanced breast cancer. As part of this robust clinical investigation, the trial continues to enroll participants, promising to yield critical data on the treatment's effectiveness.
Further Trials of Gedatolisib
In addition to VIKTORIA-1, Celcuity is conducting other studies, including a Phase 1b/2 trial known as CELC-G-201. This trial examines the use of gedatolisib in combination with darolutamide for patients battling metastatic castration-resistant prostate cancer. Furthermore, another Phase 3 trial, VIKTORIA-2, is underway, which explores the effects of gedatolisib paired with a CDK4/6 inhibitor and fulvestrant for first-line treatment in HR+/HER2- advanced breast cancer patients.
Learn More About Celcuity
Celcuity is committed to advancing cancer treatment through innovative research and clinical excellence. The company is headquartered in Minneapolis and actively works towards bringing newer, more effective therapies to market. Investors and interested parties can find additional information about Celcuity’s ambitious projects and their pipeline on their official platform, fostering transparency and open communication with stakeholders.
To connect and stay updated with the latest news, you can follow Celcuity on various social media outlets.
Frequently Asked Questions
1. What is Celcuity Inc. primarily focused on?
Celcuity Inc. is primarily focused on developing targeted therapies for the treatment of various solid tumors.
2. Who will present at the investor conferences?
Brian Sullivan, the CEO and co-founder of Celcuity, will represent the company at these conferences.
3. What is gedatolisib?
Gedatolisib is Celcuity's lead therapeutic candidate that targets the PI3K/AKT/mTOR pathway, which is vital in many cancers.
4. Where can I access the webcasts of the conferences?
The webcasts can be accessed on the Investors section of Celcuity's official website.
5. What are the key ongoing clinical trials at Celcuity?
Key ongoing clinical trials include the VIKTORIA-1 and VIKTORIA-2 studies, evaluating gedatolisib in combination with other therapies for advanced breast cancer.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
